Paracetamol (Acetaminophen): Use, Composition, Brand Names

Paracetamol, also known as acetaminophen, is a widely used non-opioid analgesic and antipyretic medication. It is employed primarily for the relief of mild to moderate pain and the reduction of fever. Available over-the-counter in many countries, it is one of the most commonly used drugs globally, found in pure form or in combination with other agents in hundreds of preparations.

First introduced clinically in the late 19th century, paracetamol has become a staple in household medicine cabinets due to its favorable safety profile when used as directed, though it carries risks of liver toxicity with overuse or overdose.

Names and Classification

Common Names: Paracetamol (international name, used in most countries outside the US); Acetaminophen (US name).

Synonyms: 4-(Acetylamino)phenol, 4-Acetamidophenol, 4′-Hydroxyacetanilide, Acenol, Acetaminofén, Acétaminophène, APAP, N-Acetyl-p-aminophenol, p-Acetamidophenol, p-Acetaminophenol, p-Acetylaminophenol, p-Hydroxy-acetanilid, p-Hydroxyacetanilide, p-Hydroxyphenolacetamide, Paracétamol, Paracetamolum.

Classification: Non-opioid analgesic; Antipyretic; Derivative of p-aminophenol. It is classified under ATC code N02BE01 (paracetamol) and various combination codes (e.g., N02BE51 for combinations excluding psycholeptics).

Brand Names: Acephen, Acetadryl, Allzital, Apadaz, Arthriten Inflammatory Pain, Bupap, Butapap, Cetafen, Children’s Silapap, Combogesic, Coricidin Hbp Cold & Flu, Darvocet-N, Dayquil Sinex, Diphen, Dolofin, Dologen, Dologesic Reformulated Jun 2016, Duralgina, Dvorah, Endocet, Exaprin, Excedrin, Excedrin PM Triple Action, Excedrin Tension Headache, Feverall, Fioricet, Fioricet With Codeine, Goody’s Back & Body Pain Relief, Goody’s Body Pain, Goody’s Extra Strength, Goody’s Headache Relief Shot, Goody’s PM, Hycet, Legatrin PM, Little Fevers, Lorcet, Lortab, Mapap, Mersyndol, Midol Complete, Midol Cramps & Bodyaches, Nalocet, Norco, Orbivan, Pamprin Max Formula, Pamprin Multi-symptom, Panadol, Pediacare Children’s Fever Reducer Pain Reliever, Percocet, Percogesic Reformulated Jan 2011, Pharbetol, Premsyn Pms, Prolate, Rivacocet, Robaxacet, Robaxacet-8, Roxicet, Sudafed PE Sinus Headache, Tactinal, Tencon, Trezix, Triatec, Triatec-30, Triatec-8, Tylenol, Tylenol PM, Tylenol With Codeine, Ultracet, Vanatol, Vanatol S, Vanquish, Xodol, Xolox, Zamicet, Zflex, Zydone. International brands include Acamol, Aceta Elixir, Aceta Tablets, Acetalgin, Actamin, Actimol, Algotropyl, Alvedon, Aminofen, Anacin-3, Anhiba, Apacet, Banesin, Calpol, Conacetol, Dafalgan, Dapa X-S, Disprol, Doliprane, Dolprone, Dymadon, Dypap, Enelfa, Febridol, Febrilix, Finimal, Gelocatil, Genapap, Genebs, Injectapap, Liquiprin, Napafen, Oraphen-PD, Paldesic, Panofen, Paraspen, Parmol, Redutemp, Rounox, Salzone, Snaplets-FR, St. Joseph Fever Reducer, Suppap, Tapanol, Valorin.

Chemical Properties and Specifications

Paracetamol is a white, odorless crystalline powder that forms large monoclinic prisms from water. It has a melting point of 169–170.5 °C and is stable when dry and pure up to 45 °C, but can degrade if contaminated or in humid conditions. It is slightly light-sensitive in solution, with degradation catalyzed by acids or bases.

The following table summarizes key specifications:

Pharmacology

Mechanism of Action

Paracetamol acts primarily in the central nervous system as a weak, reversible, isoform-nonspecific inhibitor of cyclooxygenase (COX) enzymes, particularly COX-2 and potentially COX-3 (a splice variant of COX-1), reducing prostaglandin synthesis involved in pain and fever. It may also activate transient receptor potential cation channel subfamily V member 1 (TRPV1) via its metabolite AM404, contributing to antinociception.

It inhibits prostaglandin G/H synthase 1 (PTGS1/COX-1) and 2 (PTGS2/COX-2), and acts on serotonin and noradrenaline transporters.

Pharmacokinetics

• Absorption: Rapidly absorbed from the small intestine after oral administration, with peak plasma concentrations within 30–120 minutes. Bioavailability is dose-dependent (68–90%), influenced by gastric emptying. IV administration provides immediate availability.
• Distribution: Uniformly distributed throughout body fluids; volume of distribution ~0.9 L/kg. Plasma protein binding is low (insignificant at therapeutic doses). Crosses the placenta and enters breast milk (milk:plasma ratio 0.7–1.1).
• Metabolism: Primarily hepatic, via glucuronidation (major pathway), sulfation, and minor oxidation by cytochrome P450 (mainly CYP2E1, also CYP1A2, CYP3A4, CYP2D6, CYP2A6) to form the reactive metabolite N-acetyl-p-benzoquinone imine (NAPQI), which is conjugated with glutathione. Other enzymes include UDP-glucuronosyltransferases (UGT1A1, UGT1A6, UGT1A9, UGT2B15) and sulfotransferases (SULT1A1, SULT1A3).
• Excretion: Primarily renal (2–5% unchanged); half-life 2–3.3 hours. Clearance ~352 mL/min after IV dosing. Multiphase elimination with initial half-times of 0.15–0.53 hours and terminal 2.24–3.30 hours.

Indications and Uses

Paracetamol is indicated for:

Pain Relief

Mild to moderate pain, including:

• headache (tension, migraine)
• muscular aches
• backache
• minor arthritis pain (e.g., osteoarthritis)
• toothache
• menstrual cramps
• sore throat
• sinus pain
• dental procedures
• rheumatic pain
• period pain
• fibrositis
• neuralgia
• tennis elbow
• sprains
• overexertion
• postoperative pain
• pain from colds/flu.

In combinations, it enhances effects for severe pain (e.g., with opioids). It provides small benefits in osteoarthritis but is ineffective for acute low back pain; evidence for chronic or neuropathic pain is limited.

Fever Reduction

Antipyretic for fever from infections, common cold, flu, or other causes. Benefits in critical care or dengue are unclear or minimal.

Other Uses

Temporary relief in children for teething, earache, immunizations; in preterm infants for patent ductus arteriosus closure (as effective as ibuprofen with fewer GI issues); in combinations for allergic rhinitis, upper respiratory symptoms, or migraine (e.g., with aspirin/caffeine).

It is recommended as first-line for many mild pains and fever, especially in patients intolerant to NSAIDs or with coagulation issues, but not for inflammation.

Dosage and Administration

Dosage varies by age, weight, formulation, and route. Maximum daily dose for adults: 4 g (from all sources) to avoid liver risk. Administer every 4–6 hours as needed; do not exceed recommended doses.

Adverse Effects of Paracetamol

Common:

• nausea
• stomach pain
• rash (mild).

Rare but serious:

• liver toxicity (hepatotoxicity)
• acute liver failure (especially >4 g/day or with alcohol)
• severe skin reactions (e.g., Stevens-Johnson syndrome
• toxic epidermal necrolysis—skin reddening, rash, blisters).

Long-term:

• potential increased risk of kidney cancer
• asthma (debated, especially prenatal exposure)
• hypertension.

In overdose:

• nausea
• vomiting
• abdominal pain
• leading to liver failure.

Other:

• rare hypersensitivity (anaphylaxis, angioedema)
• hematologic effects (thrombocytopenia, leukopenia)
• renal effects (acute tubular necrosis).

Contraindications and Precautions

Contraindications: Known hypersensitivity to paracetamol; severe hepatic impairment or active liver disease.

Precautions: Use caution in hepatic impairment, alcoholism (limit to 2 g/day if ≥3 drinks/day), malnutrition, G6PD deficiency, chronic heavy alcohol use, severe renal impairment (adjust dose), pregnancy (safe but monitor; potential neurodevelopmental links under study), lactation (safe in small amounts).

Avoid multiple acetaminophen products. In pediatrics, consult clinician for <6 months. Monitor for signs of overdose.

Drug Interactions

Limited potential overall, but:

• Increased Toxicity Risk: CYP inducers (e.g., rifampicin, isoniazid, carbamazepine, phenytoin, barbiturates, St. John’s wort) increase NAPQI formation. Chronic alcohol use induces CYP2E1.
• Warfarin: May increase INR and bleeding risk with long-term use.
• Absorption Alterations: Metoclopramide increases absorption; propantheline delays it. Cholestyramine reduces absorption if given soon after.
• Other: Isoniazid potentiates hepatotoxicity; probenecid inhibits glucuronidation. No significant interactions with most NSAIDs, but avoid excess with other acetaminophen sources.

Overdose and Toxicity

Overdose (>4 g/day in adults, lower in at-risk groups) can cause severe hepatotoxicity via NAPQI overload, depleting glutathione and leading to liver cell death.

• Symptoms: Initial nausea/vomiting (Phase 1, 0.5–24 hours); apparent recovery (Phase 2, 24–72 hours); hepatic necrosis (Phase 3, 72–96 hours); recovery or failure (Phase 4).
• Treatment: Activated charcoal if early; N-acetylcysteine (IV/oral) to replenish glutathione, ideally within 8–10 hours. Use Rumack-Matthew nomogram for risk assessment. Fatal without treatment; seek immediate help (Poison Control: 1-800-222-1222).

Special Populations

Pregnancy: Category A (Australia); safe when used as directed, no clear evidence of adverse outcomes, but consult clinician. Ongoing monitoring for potential links to ADHD, autism, intellectual disability from prenatal exposure.

1. Lactation: Excreted in breast milk (low amounts); safe for short-term use.
2. Pediatrics: Weight-based dosing; safe for fever/pain, but not for procedural pain in newborns. Avoid in <1 month without advice.
3. Geriatrics: No specific adjustments, but monitor for hepatic/renal function.
4. Hepatic/Renal Impairment: Reduce dose or avoid in severe cases.

Formulations and Availability

Available as tablets (325–1000 mg, uncoated/film-coated/effervescent/soluble/chewable), capsules (325–500 mg), oral liquids/suspensions (24–100 mg/mL), powders (500–1000 mg/sachet), suppositories (80–1000 mg), and IV injection (10 mg/mL). Over 200 combinations exist (e.g., with codeine, caffeine, aspirin, opioids, decongestants). OTC in most countries; prescription for IV or high-dose combinations. Labeling requires warnings for liver risk, max dose, and avoiding multiples.

History and Society

Discovered in 1877, first used clinically in 1893 for fever reduction. Marketed as Tylenol in 1955 (US); became OTC in the 1960s. Popular due to aspirin’s GI risks. Global sales exceed billions annually; common in suicide attempts, leading to pack size limits in some countries (e.g., UK). Environmental presence in water from excretion/metabolites raises concerns.

Research

Ongoing studies explore mechanisms (e.g., COX-3 role), prenatal effects, and alternatives for pain/fever. Recent (2024–2025) data on neurodevelopmental risks remain inconclusive. Investigational for conditions like patent ductus arteriosus and potential anti-cancer effects.

Sources & References

1. Ayoub, S.S. & Pryce, G., 2021. Paracetamol (acetaminophen): a familiar drug with an unexplained mechanism of action. Biochemical Pharmacology, 193, p.114799.​
2. Derry, C.J., Derry, S. & Moore, R.A., 2013. Single dose oral paracetamol (acetaminophen) for postoperative pain in adults. Cochrane Database of Systematic Reviews, (7), CD004602.​
3. Graham, G.G. et al., 2013. The modern pharmacology of paracetamol: therapeutic actions, mechanism of action, metabolism, toxicity and recent pharmacological findings. Inflammopharmacology, 21(3), pp.201–232.
4. Hinz, B. et al., 2020. Acetaminophen (paracetamol): A critical review of its mechanism of action. Handbook of Experimental Pharmacology, 260, pp.39–66.​
5. McCrae, J.C. et al., 2018. Long-term adverse effects of paracetamol – a review. British Journal of Clinical Pharmacology, 84(10), pp.2218–2230.​
   Mechanism of action, COX/COX‑3, TRPV1, AM404
6. Ayoub, S.S. et al., 2011. Acetaminophen‐induced hypothermia and antipyresis are mediated by a COX‑1 variant in the brain. FASEB Journal, 25(11), pp.4043–4056.​
7. Bertolini, A. et al., 2006. Paracetamol: new vistas of an old drug. CNS Drug Reviews, 12(3–4), pp.250–275.
8. Högestätt, E.D. et al., 2005. Conversion of paracetamol to the bioactive N‑acylphenolamine AM404 via fatty acid amide hydrolase‑dependent arachidonic acid conjugation in the nervous system. Journal of Biological Chemistry, 280(36), pp.31405–31412.​
9. Ottani, A. et al., 2006. Effect of paracetamol on changes in body temperature induced by TRPV1 receptor agonists in the rat. British Journal of Pharmacology, 149(7), pp.836–844.​
   Pharmacokinetics, metabolism (glucuronidation, sulfation, NAPQI)
10. Forrest, J.A.H. et al., 1982. Clinical pharmacokinetics of paracetamol. Clinical Pharmacokinetics, 7(2), pp.93–107.
11. Prescott, L.F., 1980. Kinetics and metabolism of paracetamol and phenacetin. British Journal of Clinical Pharmacology, 10(S2), pp.291S–298S.​
12. Kaplowitz, N., 2004. Acetaminophen hepatotoxicity: what do we know, what don’t we know, and what do we do next? Hepatology, 40(1), pp.23–26.​
13. DrugBank, 2023. Acetaminophen: Uses, Interactions, Mechanism of Action. DrugBank Online (monograph, peer‑reviewed entry).​
    Indications, guideline‑level evidence (pain, fever, osteoarthritis, back pain, PDA)
14. Hochberg, M.C. et al., 2012. American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care & Research, 64(4), pp.465–474.​
15. Malfait, A.M. et al., 2021. Paracetamol: A review of guideline recommendations. Drugs & Aging, 38(8), pp.669–688.
16. Machado, G.C. et al., 2015. Efficacy and safety of paracetamol for spinal pain and osteoarthritis: systematic review and meta‑analysis of randomized placebo‑controlled trials. BMJ, 350, h1225.​
17. Leigh, J.P. et al., 2019. The efficacy and safety of paracetamol for pain relief: systematic review of systematic reviews. Medical Journal of Australia, 210(10), pp.471–482.​
18. Oncel, M.Y. & Erdeve, O., 2016. Oral paracetamol versus ibuprofen in the management of patent ductus arteriosus in preterm infants: a randomized controlled trial. Journal of Pediatrics, 177, pp.72–77.​
    Dosing, administration, toxicity thresholds (adult/pediatric, IV)
19. Dart, R.C. et al., 2000. Acetaminophen poisoning: an evidence‑based consensus guideline for out‑of‑hospital management. Clinical Toxicology, 44(1), pp.1–18.​
20. Heubi, J.E., Barbacci, M.B. & Zimmerman, H.J., 1998. Therapeutic misadventures with acetaminophen: hepatotoxicity after multiple doses in children. Journal of Pediatrics, 132(1), pp.22–27.​
21. StatPearls, 2024. Acetaminophen. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing.​
22. Arana, A., Wentworth, C.E. & Fernandez, C., 2001. An overview of clinical pharmacology of paracetamol. Acute Pain, 4(3–4), pp.115–126.
    Adverse effects, hepatotoxicity, renal effects, blood dyscrasias, overdose management
23. Rumack, B.H. & Matthew, H., 1975. Acetaminophen poisoning and toxicity. Pediatrics, 55(6), pp.871–876.​
24. Craig, D.G.N. et al., 2010. The current management of acute liver failure: the role of acetylcysteine. Alimentary Pharmacology & Therapeutics, 31(3), pp.345–358.​
25. Larson, A.M. et al., 2005. Acetaminophen‑induced acute liver failure: results of a United States multicenter, prospective study. Hepatology, 42(6), pp.1364–1372.​
26. Clark, R. et al., 2012. The role of non‑steroidal anti‑inflammatory drugs and paracetamol in acute kidney injury. Clinical Kidney Journal, 5(Suppl 1), pp.i3–i13.​
27. McGill, M.R. & Jaeschke, H., 2013. Metabolism and disposition of acetaminophen: recent advances in relation to hepatotoxicity and diagnosis. Pharmaceutical Research, 30(9), pp.2174–2187.​
    Long‑term outcomes (asthma, kidney cancer, hypertension, neurodevelopment)
28. Henriksen, L. et al., 2013. Use of paracetamol during pregnancy and risk of asthma in offspring: a systematic review and meta‑analysis. Clinical & Experimental Allergy, 43(3), pp.363–371.​
29. Masarwa, R. et al., 2018. Prenatal exposure to acetaminophen and risk for attention deficit hyperactivity disorder and autism spectrum disorder: a systematic review and meta‑analysis. American Journal of Epidemiology, 187(8), pp.1817–1827.​
30. Ji, J. et al., 2011. Analgesic use and risk of kidney cancer: a population‑based case‑control study in Sweden. British Journal of Cancer, 104(7), pp.1190–1196.​
31. Roberts, J.M. et al., 2005. Use of acetaminophen and nonsteroidal anti‑inflammatory drugs and risk of hypertension in women. Hypertension, 46(3), pp.500–507.​
32. Karolinska Institutet, 2025. No link between paracetamol use during pregnancy and autism or ADHD in children. Karolinska Institutet News, 25 September 2025.​
    Drug interactions, special populations (hepatic/renal impairment, pregnancy, lactation, geriatrics)
33. Temple, A.R. et al., 2010. Acetaminophen toxicity: an evidence‑based consensus guideline for out‑of‑hospital management. Clinical Toxicology, 48(2), pp.147–168.​
34. Lesko, S.M. & Mitchell, A.A., 1999. The safety of acetaminophen and ibuprofen among children younger than two years old. Pediatrics, 104(4), e39.​
35. Allegaert, K. et al., 2011. Paracetamol pharmacokinetics and metabolism in neonates: a review. Current Pharmaceutical Design, 17(26), pp.2750–2762.​
36. Anderson, B.J., 2008. Paracetamol (acetaminophen): mechanisms of action. Paediatric Anaesthesia, 18(10), pp.915–921.​
37. Laine, K. et al., 2009. Pharmacokinetics of paracetamol during pregnancy and after delivery. European Journal of Clinical Pharmacology, 65(10), pp.1085–1091.​
    Formulations, modified‑release, regulatory/societal aspects
38. Benson, M. et al., 2009. Patient preference for sustained‑release versus standard paracetamol in knee osteoarthritis: a multicentre, randomized, open‑label, two‑way crossover study. Journal of International Medical Research, 37(5), pp.1321–1335.​
39. Tay, S. et al., 2019. Efficacy and safety of modified‑release paracetamol for acute and chronic pain: protocol for a systematic review. BMJ Open, 9(10), e031980.​
40. Hawton, K. et al., 2013. Long term effect of reduced pack sizes of paracetamol on poisoning deaths and liver transplant activity in England and Wales: interrupted time series analyses. BMJ, 346, f403.​
41. World Health Organization, 2019. WHO Model List of Essential Medicines: 21st List. Geneva: WHO. (paracetamol section).